Companies /Healthcare

Immunocore Holdings plc

NASDAQ: IMCR Biotechnology
$29.94
▼ $0.54 (−1.76%) today
Markets closed · 3:52am ET

24/7 Wall St. View

IMCR at a Glance

Valuation
Market cap
$1.5B
Profitability
Revenue (TTM)
$429.3M
Profit margin
-7.5%
EPS (TTM)
$-0.64
Price
52-week range
$28 – $41
Street target
$59.40

Headquartered in 92 Park Drive, Abingdon Fiscal year ends December NASDAQ: IMCR immunocore.com

About Immunocore

Immunocore is a commercial-stage biotechnology company developing T cell receptor (TCR) bispecific immunotherapies under its proprietary ImmTAX platform for cancer, infectious diseases and autoimmune diseases. Its revenue comes from KIMMTRAK (tebentafusp-tebn), a gp100-targeting TCR bispecific approved in 39 countries, including the U.S., EU, UK, Canada and Australia. KIMMTRAK treats HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma and is sold in the United States, Europe and international markets. The company is pursuing label expansion for KIMMTRAK into previously treated advanced cutaneous melanoma (Phase 3 TEBE-AM) and adjuvant uveal melanoma (EORTC Phase 3 ATOM). Its pipeline spans three platforms. ImmTAC oncology candidates include the PRAME-targeting brenetafusp, in Phase 3 PRISM-MEL-301 for first-line cutaneous melanoma and in trials for ovarian cancer, NSCLC and uveal melanoma, plus the half-life-extended IMC-P115C. ImmTAV candidates such as IMC-M113V aim at a functional cure for HIV. ImmTAAI tissue-specific PD-1 agonist candidates include IMC-S118AI for type 1 diabetes and IMC-U120AI for dermatological diseases such as atopic dermatitis. The company also runs the KIMMTRAKConnect patient access program in the U.S. Updated

IMCR Coverage

Frequently Asked Questions

What does Immunocore do?

Immunocore is a commercial-stage biotechnology company developing T cell receptor (TCR) bispecific immunotherapies under its proprietary ImmTAX platform for cancer, infectious diseases and autoimmune diseases.

What is the IMCR stock price target?

The Wall Street consensus 12-month price target for IMCR is $59.40. IMCR price prediction →